nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—PDGFRA—melanoma	0.18	0.373	CbGaD
Ponatinib—KDR—melanoma	0.14	0.29	CbGaD
Ponatinib—KIT—melanoma	0.132	0.274	CbGaD
Ponatinib—ABCG2—Vemurafenib—melanoma	0.0513	0.279	CbGbCtD
Ponatinib—ABCG2—Dactinomycin—melanoma	0.0341	0.185	CbGbCtD
Ponatinib—ABCB1—melanoma	0.0305	0.0631	CbGaD
Ponatinib—CYP3A4—Temozolomide—melanoma	0.0202	0.11	CbGbCtD
Ponatinib—ABCG2—Docetaxel—melanoma	0.0176	0.0957	CbGbCtD
Ponatinib—CYP2D6—Vemurafenib—melanoma	0.0174	0.0948	CbGbCtD
Ponatinib—ABCB1—Dactinomycin—melanoma	0.0123	0.0668	CbGbCtD
Ponatinib—CYP3A4—Vemurafenib—melanoma	0.0111	0.0603	CbGbCtD
Ponatinib—CYP3A5—Docetaxel—melanoma	0.00975	0.053	CbGbCtD
Ponatinib—ABCB1—Docetaxel—melanoma	0.00635	0.0345	CbGbCtD
Ponatinib—CYP3A4—Docetaxel—melanoma	0.0038	0.0207	CbGbCtD
Ponatinib—FGFR3—appendage—melanoma	0.00364	0.069	CbGeAlD
Ponatinib—FGFR3—skin epidermis—melanoma	0.00303	0.0574	CbGeAlD
Ponatinib—KDR—umbilical vein—melanoma	0.00238	0.0451	CbGeAlD
Ponatinib—KDR—hindlimb—melanoma	0.00218	0.0412	CbGeAlD
Ponatinib—FGFR3—hair follicle—melanoma	0.00216	0.0409	CbGeAlD
Ponatinib—FGFR2—skin epidermis—melanoma	0.00198	0.0376	CbGeAlD
Ponatinib—KDR—appendage—melanoma	0.00187	0.0354	CbGeAlD
Ponatinib—Nilotinib—EPHA2—melanoma	0.00162	0.352	CrCbGaD
Ponatinib—TEK—endothelium—melanoma	0.00138	0.0261	CbGeAlD
Ponatinib—KIT—skin epidermis—melanoma	0.00138	0.0261	CbGeAlD
Ponatinib—TEK—blood vessel—melanoma	0.00127	0.0241	CbGeAlD
Ponatinib—SRC—endothelium—melanoma	0.00123	0.0232	CbGeAlD
Ponatinib—SRC—blood vessel—melanoma	0.00113	0.0214	CbGeAlD
Ponatinib—KDR—endothelium—melanoma	0.00113	0.0214	CbGeAlD
Ponatinib—KDR—blood vessel—melanoma	0.00104	0.0197	CbGeAlD
Ponatinib—KIT—endothelium—melanoma	0.000999	0.0189	CbGeAlD
Ponatinib—RET—neck—melanoma	0.000999	0.0189	CbGeAlD
Ponatinib—FGFR2—neck—melanoma	0.000949	0.018	CbGeAlD
Ponatinib—FGFR3—skin of body—melanoma	0.000938	0.0178	CbGeAlD
Ponatinib—BCR—eye—melanoma	0.000933	0.0177	CbGeAlD
Ponatinib—KIT—blood vessel—melanoma	0.000921	0.0175	CbGeAlD
Ponatinib—FGFR4—head—melanoma	0.000897	0.017	CbGeAlD
Ponatinib—FGFR3—mammalian vulva—melanoma	0.000856	0.0162	CbGeAlD
Ponatinib—KDR—neck—melanoma	0.000744	0.0141	CbGeAlD
Ponatinib—BCR—mammalian vulva—melanoma	0.00074	0.014	CbGeAlD
Ponatinib—FGFR2—eye—melanoma	0.000706	0.0134	CbGeAlD
Ponatinib—KIT—neck—melanoma	0.000659	0.0125	CbGeAlD
Ponatinib—FGFR1—mammalian vulva—melanoma	0.000659	0.0125	CbGeAlD
Ponatinib—Nilotinib—PDGFRA—melanoma	0.000655	0.142	CrCbGaD
Ponatinib—FGFR4—lymph node—melanoma	0.000628	0.0119	CbGeAlD
Ponatinib—LYN—head—melanoma	0.000615	0.0117	CbGeAlD
Ponatinib—FGFR2—skin of body—melanoma	0.000614	0.0116	CbGeAlD
Ponatinib—FGFR3—head—melanoma	0.000612	0.0116	CbGeAlD
Ponatinib—SRC—eye—melanoma	0.000601	0.0114	CbGeAlD
Ponatinib—Nilotinib—BRAF—melanoma	0.000599	0.13	CrCbGaD
Ponatinib—SRC—retina—melanoma	0.000596	0.0113	CbGeAlD
Ponatinib—LCK—mammalian vulva—melanoma	0.00059	0.0112	CbGeAlD
Ponatinib—KDR—eye—melanoma	0.000553	0.0105	CbGeAlD
Ponatinib—KDR—retina—melanoma	0.000548	0.0104	CbGeAlD
Ponatinib—Imatinib—PDGFRA—melanoma	0.000547	0.119	CrCbGaD
Ponatinib—BCR—head—melanoma	0.00053	0.01	CbGeAlD
Ponatinib—SRC—skin of body—melanoma	0.000523	0.00991	CbGeAlD
Ponatinib—Nilotinib—KIT—melanoma	0.000481	0.104	CrCbGaD
Ponatinib—KDR—mammalian vulva—melanoma	0.000439	0.00832	CbGeAlD
Ponatinib—ABL1—eye—melanoma	0.000427	0.00809	CbGeAlD
Ponatinib—KIT—skin of body—melanoma	0.000426	0.00808	CbGeAlD
Ponatinib—ABL1—retina—melanoma	0.000423	0.00801	CbGeAlD
Ponatinib—RET—head—melanoma	0.000422	0.00799	CbGeAlD
Ponatinib—Imatinib—KIT—melanoma	0.000401	0.0871	CrCbGaD
Ponatinib—FGFR2—head—melanoma	0.000401	0.00759	CbGeAlD
Ponatinib—KIT—mammalian vulva—melanoma	0.000389	0.00737	CbGeAlD
Ponatinib—TEK—head—melanoma	0.000384	0.00728	CbGeAlD
Ponatinib—ABL1—skin of body—melanoma	0.000371	0.00703	CbGeAlD
Ponatinib—BCR—lymph node—melanoma	0.000371	0.00703	CbGeAlD
Ponatinib—FLT3—lymph node—melanoma	0.000368	0.00698	CbGeAlD
Ponatinib—PDGFRA—head—melanoma	0.000348	0.0066	CbGeAlD
Ponatinib—SRC—head—melanoma	0.000341	0.00647	CbGeAlD
Ponatinib—ABL1—mammalian vulva—melanoma	0.000339	0.00642	CbGeAlD
Ponatinib—FGFR1—lymph node—melanoma	0.00033	0.00625	CbGeAlD
Ponatinib—KDR—head—melanoma	0.000314	0.00595	CbGeAlD
Ponatinib—LCK—lymph node—melanoma	0.000295	0.0056	CbGeAlD
Ponatinib—RET—lymph node—melanoma	0.000295	0.0056	CbGeAlD
Ponatinib—KIT—head—melanoma	0.000278	0.00527	CbGeAlD
Ponatinib—TEK—lymph node—melanoma	0.000269	0.0051	CbGeAlD
Ponatinib—ABCB1—blood vessel—melanoma	0.000249	0.00473	CbGeAlD
Ponatinib—PDGFRA—lymph node—melanoma	0.000244	0.00462	CbGeAlD
Ponatinib—ABL1—head—melanoma	0.000242	0.00459	CbGeAlD
Ponatinib—SRC—lymph node—melanoma	0.000239	0.00453	CbGeAlD
Ponatinib—KDR—lymph node—melanoma	0.00022	0.00417	CbGeAlD
Ponatinib—ABCG2—mammalian vulva—melanoma	0.000214	0.00405	CbGeAlD
Ponatinib—Pneumonia—Carmustine—melanoma	0.000203	0.00207	CcSEcCtD
Ponatinib—Erectile dysfunction—Temozolomide—melanoma	0.000201	0.00205	CcSEcCtD
Ponatinib—Sepsis—Docetaxel—melanoma	0.000201	0.00205	CcSEcCtD
Ponatinib—Weight decreased—Temozolomide—melanoma	0.000198	0.00202	CcSEcCtD
Ponatinib—Neuropathy peripheral—Carmustine—melanoma	0.000198	0.00202	CcSEcCtD
Ponatinib—Hyperglycaemia—Temozolomide—melanoma	0.000197	0.00201	CcSEcCtD
Ponatinib—Stomatitis—Carmustine—melanoma	0.000197	0.00201	CcSEcCtD
Ponatinib—Urinary tract infection—Carmustine—melanoma	0.000196	0.002	CcSEcCtD
Ponatinib—Pneumonia—Temozolomide—melanoma	0.000196	0.002	CcSEcCtD
Ponatinib—Infestation—Temozolomide—melanoma	0.000195	0.00199	CcSEcCtD
Ponatinib—Infestation NOS—Temozolomide—melanoma	0.000195	0.00199	CcSEcCtD
Ponatinib—KIT—lymph node—melanoma	0.000195	0.00369	CbGeAlD
Ponatinib—Blood alkaline phosphatase increased—Docetaxel—melanoma	0.000193	0.00197	CcSEcCtD
Ponatinib—Flushing—Bleomycin—melanoma	0.000192	0.00196	CcSEcCtD
Ponatinib—Body temperature increased—Vemurafenib—melanoma	0.000192	0.00196	CcSEcCtD
Ponatinib—Neuropathy peripheral—Temozolomide—melanoma	0.000191	0.00195	CcSEcCtD
Ponatinib—Stomatitis—Temozolomide—melanoma	0.00019	0.00194	CcSEcCtD
Ponatinib—Urinary tract infection—Temozolomide—melanoma	0.000189	0.00193	CcSEcCtD
Ponatinib—Chills—Bleomycin—melanoma	0.000186	0.0019	CcSEcCtD
Ponatinib—Cardiac failure congestive—Docetaxel—melanoma	0.000185	0.00189	CcSEcCtD
Ponatinib—Hepatobiliary disease—Temozolomide—melanoma	0.000184	0.00188	CcSEcCtD
Ponatinib—Alopecia—Bleomycin—melanoma	0.000183	0.00187	CcSEcCtD
Ponatinib—Haemoglobin—Carmustine—melanoma	0.000182	0.00186	CcSEcCtD
Ponatinib—Haemorrhage—Carmustine—melanoma	0.000181	0.00185	CcSEcCtD
Ponatinib—Erythema—Bleomycin—melanoma	0.000181	0.00184	CcSEcCtD
Ponatinib—Hypoaesthesia—Carmustine—melanoma	0.00018	0.00184	CcSEcCtD
Ponatinib—Hot flush—Docetaxel—melanoma	0.00018	0.00183	CcSEcCtD
Ponatinib—Flushing—Dactinomycin—melanoma	0.00018	0.00183	CcSEcCtD
Ponatinib—Oedema peripheral—Carmustine—melanoma	0.000178	0.00182	CcSEcCtD
Ponatinib—Menopausal symptoms—Docetaxel—melanoma	0.000178	0.00182	CcSEcCtD
Ponatinib—Connective tissue disorder—Carmustine—melanoma	0.000178	0.00182	CcSEcCtD
Ponatinib—Atrial fibrillation—Docetaxel—melanoma	0.000177	0.00181	CcSEcCtD
Ponatinib—Haemoglobin—Temozolomide—melanoma	0.000176	0.00179	CcSEcCtD
Ponatinib—Haemorrhage—Temozolomide—melanoma	0.000175	0.00179	CcSEcCtD
Ponatinib—Asthenia—Vemurafenib—melanoma	0.000175	0.00178	CcSEcCtD
Ponatinib—Visual impairment—Carmustine—melanoma	0.000174	0.00178	CcSEcCtD
Ponatinib—Hypoaesthesia—Temozolomide—melanoma	0.000174	0.00178	CcSEcCtD
Ponatinib—Chills—Dactinomycin—melanoma	0.000174	0.00177	CcSEcCtD
Ponatinib—Oedema peripheral—Temozolomide—melanoma	0.000172	0.00176	CcSEcCtD
Ponatinib—Cardiac failure—Docetaxel—melanoma	0.000172	0.00176	CcSEcCtD
Ponatinib—Pruritus—Vemurafenib—melanoma	0.000172	0.00176	CcSEcCtD
Ponatinib—Connective tissue disorder—Temozolomide—melanoma	0.000172	0.00175	CcSEcCtD
Ponatinib—Lethargy—Docetaxel—melanoma	0.000172	0.00175	CcSEcCtD
Ponatinib—Alopecia—Dactinomycin—melanoma	0.000171	0.00174	CcSEcCtD
Ponatinib—ABL1—lymph node—melanoma	0.00017	0.00321	CbGeAlD
Ponatinib—Eye disorder—Carmustine—melanoma	0.000169	0.00173	CcSEcCtD
Ponatinib—Hyponatraemia—Docetaxel—melanoma	0.000169	0.00172	CcSEcCtD
Ponatinib—Visual impairment—Temozolomide—melanoma	0.000169	0.00172	CcSEcCtD
Ponatinib—Erythema—Dactinomycin—melanoma	0.000168	0.00172	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.000168	0.00172	CcSEcCtD
Ponatinib—Pain in extremity—Docetaxel—melanoma	0.000168	0.00172	CcSEcCtD
Ponatinib—Flushing—Carmustine—melanoma	0.000168	0.00171	CcSEcCtD
Ponatinib—Anaemia—Bleomycin—melanoma	0.000167	0.0017	CcSEcCtD
Ponatinib—Diarrhoea—Vemurafenib—melanoma	0.000166	0.0017	CcSEcCtD
Ponatinib—Migraine—Docetaxel—melanoma	0.000166	0.00169	CcSEcCtD
Ponatinib—Eye disorder—Temozolomide—melanoma	0.000164	0.00167	CcSEcCtD
Ponatinib—Cardiac disorder—Temozolomide—melanoma	0.000162	0.00166	CcSEcCtD
Ponatinib—Flushing—Temozolomide—melanoma	0.000162	0.00166	CcSEcCtD
Ponatinib—Arrhythmia—Carmustine—melanoma	0.000162	0.00165	CcSEcCtD
Ponatinib—Leukopenia—Bleomycin—melanoma	0.000162	0.00165	CcSEcCtD
Ponatinib—Dizziness—Vemurafenib—melanoma	0.000161	0.00164	CcSEcCtD
Ponatinib—Alopecia—Carmustine—melanoma	0.00016	0.00163	CcSEcCtD
Ponatinib—Angiopathy—Temozolomide—melanoma	0.000159	0.00162	CcSEcCtD
Ponatinib—Mental disorder—Carmustine—melanoma	0.000159	0.00162	CcSEcCtD
Ponatinib—Mediastinal disorder—Temozolomide—melanoma	0.000158	0.00161	CcSEcCtD
Ponatinib—Malnutrition—Carmustine—melanoma	0.000158	0.00161	CcSEcCtD
Ponatinib—Erythema—Carmustine—melanoma	0.000158	0.00161	CcSEcCtD
Ponatinib—Cough—Bleomycin—melanoma	0.000158	0.00161	CcSEcCtD
Ponatinib—Chills—Temozolomide—melanoma	0.000157	0.0016	CcSEcCtD
Ponatinib—Dehydration—Docetaxel—melanoma	0.000156	0.0016	CcSEcCtD
Ponatinib—Anaemia—Dactinomycin—melanoma	0.000156	0.00159	CcSEcCtD
Ponatinib—Vomiting—Vemurafenib—melanoma	0.000155	0.00158	CcSEcCtD
Ponatinib—Alopecia—Temozolomide—melanoma	0.000155	0.00158	CcSEcCtD
Ponatinib—Dry skin—Docetaxel—melanoma	0.000154	0.00157	CcSEcCtD
Ponatinib—Myalgia—Bleomycin—melanoma	0.000154	0.00157	CcSEcCtD
Ponatinib—Rash—Vemurafenib—melanoma	0.000153	0.00156	CcSEcCtD
Ponatinib—Mental disorder—Temozolomide—melanoma	0.000153	0.00156	CcSEcCtD
Ponatinib—Dermatitis—Vemurafenib—melanoma	0.000153	0.00156	CcSEcCtD
Ponatinib—Back pain—Carmustine—melanoma	0.000152	0.00156	CcSEcCtD
Ponatinib—Headache—Vemurafenib—melanoma	0.000152	0.00155	CcSEcCtD
Ponatinib—Erythema—Temozolomide—melanoma	0.000152	0.00155	CcSEcCtD
Ponatinib—Malnutrition—Temozolomide—melanoma	0.000152	0.00155	CcSEcCtD
Ponatinib—Breast disorder—Docetaxel—melanoma	0.000152	0.00155	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000151	0.00155	CcSEcCtD
Ponatinib—Leukopenia—Dactinomycin—melanoma	0.000151	0.00154	CcSEcCtD
Ponatinib—Nasopharyngitis—Docetaxel—melanoma	0.00015	0.00153	CcSEcCtD
Ponatinib—Vision blurred—Carmustine—melanoma	0.000149	0.00152	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Docetaxel—melanoma	0.000148	0.00151	CcSEcCtD
Ponatinib—Oedema—Bleomycin—melanoma	0.000147	0.0015	CcSEcCtD
Ponatinib—Back pain—Temozolomide—melanoma	0.000147	0.0015	CcSEcCtD
Ponatinib—Infection—Bleomycin—melanoma	0.000146	0.00149	CcSEcCtD
Ponatinib—Anaemia—Carmustine—melanoma	0.000146	0.00149	CcSEcCtD
Ponatinib—Nausea—Vemurafenib—melanoma	0.000144	0.00147	CcSEcCtD
Ponatinib—Thrombocytopenia—Bleomycin—melanoma	0.000144	0.00147	CcSEcCtD
Ponatinib—Vision blurred—Temozolomide—melanoma	0.000144	0.00146	CcSEcCtD
Ponatinib—Myalgia—Dactinomycin—melanoma	0.000143	0.00146	CcSEcCtD
Ponatinib—Angina pectoris—Docetaxel—melanoma	0.000142	0.00144	CcSEcCtD
Ponatinib—Leukopenia—Carmustine—melanoma	0.000141	0.00144	CcSEcCtD
Ponatinib—Anaemia—Temozolomide—melanoma	0.000141	0.00144	CcSEcCtD
Ponatinib—Pancytopenia—Docetaxel—melanoma	0.000138	0.00141	CcSEcCtD
Ponatinib—Oedema—Dactinomycin—melanoma	0.000137	0.0014	CcSEcCtD
Ponatinib—Infection—Dactinomycin—melanoma	0.000137	0.00139	CcSEcCtD
Ponatinib—Leukopenia—Temozolomide—melanoma	0.000136	0.00139	CcSEcCtD
Ponatinib—Hypertension—Carmustine—melanoma	0.000136	0.00139	CcSEcCtD
Ponatinib—Neutropenia—Docetaxel—melanoma	0.000136	0.00139	CcSEcCtD
Ponatinib—Thrombocytopenia—Dactinomycin—melanoma	0.000135	0.00137	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Bleomycin—melanoma	0.000134	0.00137	CcSEcCtD
Ponatinib—Myalgia—Carmustine—melanoma	0.000134	0.00137	CcSEcCtD
Ponatinib—Cough—Temozolomide—melanoma	0.000133	0.00136	CcSEcCtD
Ponatinib—Paraesthesia—Bleomycin—melanoma	0.000132	0.00135	CcSEcCtD
Ponatinib—Weight decreased—Docetaxel—melanoma	0.000132	0.00134	CcSEcCtD
Ponatinib—ABCB1—retina—melanoma	0.000132	0.00249	CbGeAlD
Ponatinib—Hypertension—Temozolomide—melanoma	0.000131	0.00134	CcSEcCtD
Ponatinib—Dyspnoea—Bleomycin—melanoma	0.000131	0.00134	CcSEcCtD
Ponatinib—Pneumonia—Docetaxel—melanoma	0.00013	0.00133	CcSEcCtD
Ponatinib—Myalgia—Temozolomide—melanoma	0.00013	0.00132	CcSEcCtD
Ponatinib—Arthralgia—Temozolomide—melanoma	0.00013	0.00132	CcSEcCtD
Ponatinib—Infestation—Docetaxel—melanoma	0.00013	0.00132	CcSEcCtD
Ponatinib—Infestation NOS—Docetaxel—melanoma	0.00013	0.00132	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000129	0.00131	CcSEcCtD
Ponatinib—Oedema—Carmustine—melanoma	0.000129	0.00131	CcSEcCtD
Ponatinib—Decreased appetite—Bleomycin—melanoma	0.000128	0.00131	CcSEcCtD
Ponatinib—Infection—Carmustine—melanoma	0.000128	0.0013	CcSEcCtD
Ponatinib—Acute coronary syndrome—Docetaxel—melanoma	0.000128	0.0013	CcSEcCtD
Ponatinib—Myocardial infarction—Docetaxel—melanoma	0.000127	0.0013	CcSEcCtD
Ponatinib—Neuropathy peripheral—Docetaxel—melanoma	0.000127	0.0013	CcSEcCtD
Ponatinib—Dry mouth—Temozolomide—melanoma	0.000127	0.00129	CcSEcCtD
Ponatinib—Jaundice—Docetaxel—melanoma	0.000126	0.00129	CcSEcCtD
Ponatinib—Stomatitis—Docetaxel—melanoma	0.000126	0.00129	CcSEcCtD
Ponatinib—Pain—Bleomycin—melanoma	0.000126	0.00129	CcSEcCtD
Ponatinib—Thrombocytopenia—Carmustine—melanoma	0.000126	0.00129	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000125	0.00128	CcSEcCtD
Ponatinib—Oedema—Temozolomide—melanoma	0.000124	0.00127	CcSEcCtD
Ponatinib—Infection—Temozolomide—melanoma	0.000123	0.00126	CcSEcCtD
Ponatinib—Hepatobiliary disease—Docetaxel—melanoma	0.000123	0.00125	CcSEcCtD
Ponatinib—Epistaxis—Docetaxel—melanoma	0.000122	0.00125	CcSEcCtD
Ponatinib—Nervous system disorder—Temozolomide—melanoma	0.000122	0.00124	CcSEcCtD
Ponatinib—Thrombocytopenia—Temozolomide—melanoma	0.000122	0.00124	CcSEcCtD
Ponatinib—Skin disorder—Temozolomide—melanoma	0.000121	0.00123	CcSEcCtD
Ponatinib—Hyperhidrosis—Temozolomide—melanoma	0.00012	0.00123	CcSEcCtD
Ponatinib—Decreased appetite—Dactinomycin—melanoma	0.000119	0.00122	CcSEcCtD
Ponatinib—Fatigue—Dactinomycin—melanoma	0.000118	0.00121	CcSEcCtD
Ponatinib—Pain—Dactinomycin—melanoma	0.000118	0.0012	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Carmustine—melanoma	0.000117	0.0012	CcSEcCtD
Ponatinib—Haemoglobin—Docetaxel—melanoma	0.000117	0.00119	CcSEcCtD
Ponatinib—Body temperature increased—Bleomycin—melanoma	0.000116	0.00119	CcSEcCtD
Ponatinib—Haemorrhage—Docetaxel—melanoma	0.000116	0.00119	CcSEcCtD
Ponatinib—Insomnia—Carmustine—melanoma	0.000116	0.00119	CcSEcCtD
Ponatinib—Hypoaesthesia—Docetaxel—melanoma	0.000116	0.00118	CcSEcCtD
Ponatinib—Paraesthesia—Carmustine—melanoma	0.000116	0.00118	CcSEcCtD
Ponatinib—Dyspnoea—Carmustine—melanoma	0.000115	0.00117	CcSEcCtD
Ponatinib—Oedema peripheral—Docetaxel—melanoma	0.000115	0.00117	CcSEcCtD
Ponatinib—Connective tissue disorder—Docetaxel—melanoma	0.000114	0.00117	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Temozolomide—melanoma	0.000113	0.00116	CcSEcCtD
Ponatinib—Insomnia—Temozolomide—melanoma	0.000112	0.00115	CcSEcCtD
Ponatinib—Gastrointestinal pain—Dactinomycin—melanoma	0.000112	0.00115	CcSEcCtD
Ponatinib—Visual impairment—Docetaxel—melanoma	0.000112	0.00114	CcSEcCtD
Ponatinib—Decreased appetite—Carmustine—melanoma	0.000112	0.00114	CcSEcCtD
Ponatinib—Paraesthesia—Temozolomide—melanoma	0.000112	0.00114	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Carmustine—melanoma	0.000111	0.00113	CcSEcCtD
Ponatinib—Nilotinib—ABCB1—melanoma	0.000111	0.0241	CrCbGaD
Ponatinib—Dyspnoea—Temozolomide—melanoma	0.000111	0.00113	CcSEcCtD
Ponatinib—Constipation—Carmustine—melanoma	0.00011	0.00112	CcSEcCtD
Ponatinib—Pain—Carmustine—melanoma	0.00011	0.00112	CcSEcCtD
Ponatinib—Dyspepsia—Temozolomide—melanoma	0.000109	0.00112	CcSEcCtD
Ponatinib—Eye disorder—Docetaxel—melanoma	0.000109	0.00111	CcSEcCtD
Ponatinib—Abdominal pain—Dactinomycin—melanoma	0.000109	0.00111	CcSEcCtD
Ponatinib—Body temperature increased—Dactinomycin—melanoma	0.000109	0.00111	CcSEcCtD
Ponatinib—Decreased appetite—Temozolomide—melanoma	0.000108	0.0011	CcSEcCtD
Ponatinib—Flushing—Docetaxel—melanoma	0.000108	0.0011	CcSEcCtD
Ponatinib—Cardiac disorder—Docetaxel—melanoma	0.000108	0.0011	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Temozolomide—melanoma	0.000107	0.0011	CcSEcCtD
Ponatinib—Fatigue—Temozolomide—melanoma	0.000107	0.00109	CcSEcCtD
Ponatinib—ABCG2—lymph node—melanoma	0.000107	0.00203	CbGeAlD
Ponatinib—Pain—Temozolomide—melanoma	0.000106	0.00108	CcSEcCtD
Ponatinib—Constipation—Temozolomide—melanoma	0.000106	0.00108	CcSEcCtD
Ponatinib—Asthenia—Bleomycin—melanoma	0.000106	0.00108	CcSEcCtD
Ponatinib—Angiopathy—Docetaxel—melanoma	0.000106	0.00108	CcSEcCtD
Ponatinib—ABCB1—mammalian vulva—melanoma	0.000105	0.002	CbGeAlD
Ponatinib—Gastrointestinal pain—Carmustine—melanoma	0.000105	0.00107	CcSEcCtD
Ponatinib—Mediastinal disorder—Docetaxel—melanoma	0.000105	0.00107	CcSEcCtD
Ponatinib—CYP2D6—head—melanoma	0.000105	0.00198	CbGeAlD
Ponatinib—Chills—Docetaxel—melanoma	0.000104	0.00107	CcSEcCtD
Ponatinib—Pruritus—Bleomycin—melanoma	0.000104	0.00106	CcSEcCtD
Ponatinib—Arrhythmia—Docetaxel—melanoma	0.000104	0.00106	CcSEcCtD
Ponatinib—Alopecia—Docetaxel—melanoma	0.000103	0.00105	CcSEcCtD
Ponatinib—Mental disorder—Docetaxel—melanoma	0.000102	0.00104	CcSEcCtD
Ponatinib—Abdominal pain—Carmustine—melanoma	0.000102	0.00104	CcSEcCtD
Ponatinib—Body temperature increased—Carmustine—melanoma	0.000102	0.00104	CcSEcCtD
Ponatinib—Gastrointestinal pain—Temozolomide—melanoma	0.000102	0.00104	CcSEcCtD
Ponatinib—Malnutrition—Docetaxel—melanoma	0.000101	0.00103	CcSEcCtD
Ponatinib—Erythema—Docetaxel—melanoma	0.000101	0.00103	CcSEcCtD
Ponatinib—Asthenia—Dactinomycin—melanoma	9.86e-05	0.00101	CcSEcCtD
Ponatinib—Abdominal pain—Temozolomide—melanoma	9.83e-05	0.001	CcSEcCtD
Ponatinib—Body temperature increased—Temozolomide—melanoma	9.83e-05	0.001	CcSEcCtD
Ponatinib—Back pain—Docetaxel—melanoma	9.8e-05	0.001	CcSEcCtD
Ponatinib—Muscle spasms—Docetaxel—melanoma	9.74e-05	0.000994	CcSEcCtD
Ponatinib—Imatinib—ALB—melanoma	9.69e-05	0.021	CrCbGaD
Ponatinib—Diarrhoea—Dactinomycin—melanoma	9.4e-05	0.00096	CcSEcCtD
Ponatinib—Vomiting—Bleomycin—melanoma	9.37e-05	0.000956	CcSEcCtD
Ponatinib—Anaemia—Docetaxel—melanoma	9.36e-05	0.000955	CcSEcCtD
Ponatinib—Rash—Bleomycin—melanoma	9.29e-05	0.000948	CcSEcCtD
Ponatinib—Dermatitis—Bleomycin—melanoma	9.28e-05	0.000947	CcSEcCtD
Ponatinib—Imatinib—ABCB1—melanoma	9.24e-05	0.0201	CrCbGaD
Ponatinib—Asthenia—Carmustine—melanoma	9.23e-05	0.000942	CcSEcCtD
Ponatinib—Leukopenia—Docetaxel—melanoma	9.07e-05	0.000925	CcSEcCtD
Ponatinib—Asthenia—Temozolomide—melanoma	8.92e-05	0.00091	CcSEcCtD
Ponatinib—Cough—Docetaxel—melanoma	8.84e-05	0.000902	CcSEcCtD
Ponatinib—Diarrhoea—Carmustine—melanoma	8.8e-05	0.000898	CcSEcCtD
Ponatinib—Pruritus—Temozolomide—melanoma	8.79e-05	0.000897	CcSEcCtD
Ponatinib—Nausea—Bleomycin—melanoma	8.75e-05	0.000893	CcSEcCtD
Ponatinib—Hypertension—Docetaxel—melanoma	8.74e-05	0.000892	CcSEcCtD
Ponatinib—Vomiting—Dactinomycin—melanoma	8.74e-05	0.000892	CcSEcCtD
Ponatinib—Rash—Dactinomycin—melanoma	8.67e-05	0.000884	CcSEcCtD
Ponatinib—Arthralgia—Docetaxel—melanoma	8.62e-05	0.00088	CcSEcCtD
Ponatinib—Myalgia—Docetaxel—melanoma	8.62e-05	0.00088	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	8.56e-05	0.000874	CcSEcCtD
Ponatinib—Dizziness—Carmustine—melanoma	8.51e-05	0.000868	CcSEcCtD
Ponatinib—Diarrhoea—Temozolomide—melanoma	8.5e-05	0.000868	CcSEcCtD
Ponatinib—Dry mouth—Docetaxel—melanoma	8.43e-05	0.000861	CcSEcCtD
Ponatinib—Oedema—Docetaxel—melanoma	8.27e-05	0.000844	CcSEcCtD
Ponatinib—Dizziness—Temozolomide—melanoma	8.22e-05	0.000839	CcSEcCtD
Ponatinib—Infection—Docetaxel—melanoma	8.21e-05	0.000838	CcSEcCtD
Ponatinib—Vomiting—Carmustine—melanoma	8.18e-05	0.000835	CcSEcCtD
Ponatinib—Nausea—Dactinomycin—melanoma	8.16e-05	0.000833	CcSEcCtD
Ponatinib—Rash—Carmustine—melanoma	8.11e-05	0.000828	CcSEcCtD
Ponatinib—Nervous system disorder—Docetaxel—melanoma	8.11e-05	0.000827	CcSEcCtD
Ponatinib—Dermatitis—Carmustine—melanoma	8.1e-05	0.000827	CcSEcCtD
Ponatinib—Thrombocytopenia—Docetaxel—melanoma	8.09e-05	0.000826	CcSEcCtD
Ponatinib—Headache—Carmustine—melanoma	8.06e-05	0.000822	CcSEcCtD
Ponatinib—Skin disorder—Docetaxel—melanoma	8.03e-05	0.000819	CcSEcCtD
Ponatinib—Vomiting—Temozolomide—melanoma	7.9e-05	0.000806	CcSEcCtD
Ponatinib—Rash—Temozolomide—melanoma	7.84e-05	0.0008	CcSEcCtD
Ponatinib—Dermatitis—Temozolomide—melanoma	7.83e-05	0.000799	CcSEcCtD
Ponatinib—Headache—Temozolomide—melanoma	7.79e-05	0.000795	CcSEcCtD
Ponatinib—Nausea—Carmustine—melanoma	7.64e-05	0.00078	CcSEcCtD
Ponatinib—ABCB1—head—melanoma	7.53e-05	0.00143	CbGeAlD
Ponatinib—Musculoskeletal discomfort—Docetaxel—melanoma	7.53e-05	0.000768	CcSEcCtD
Ponatinib—Insomnia—Docetaxel—melanoma	7.48e-05	0.000763	CcSEcCtD
Ponatinib—Paraesthesia—Docetaxel—melanoma	7.42e-05	0.000757	CcSEcCtD
Ponatinib—Nausea—Temozolomide—melanoma	7.38e-05	0.000753	CcSEcCtD
Ponatinib—Dyspnoea—Docetaxel—melanoma	7.37e-05	0.000752	CcSEcCtD
Ponatinib—Dyspepsia—Docetaxel—melanoma	7.28e-05	0.000742	CcSEcCtD
Ponatinib—Decreased appetite—Docetaxel—melanoma	7.19e-05	0.000733	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Docetaxel—melanoma	7.14e-05	0.000728	CcSEcCtD
Ponatinib—Fatigue—Docetaxel—melanoma	7.13e-05	0.000727	CcSEcCtD
Ponatinib—Pain—Docetaxel—melanoma	7.07e-05	0.000721	CcSEcCtD
Ponatinib—Constipation—Docetaxel—melanoma	7.07e-05	0.000721	CcSEcCtD
Ponatinib—Gastrointestinal pain—Docetaxel—melanoma	6.76e-05	0.00069	CcSEcCtD
Ponatinib—Abdominal pain—Docetaxel—melanoma	6.53e-05	0.000667	CcSEcCtD
Ponatinib—Body temperature increased—Docetaxel—melanoma	6.53e-05	0.000667	CcSEcCtD
Ponatinib—Asthenia—Docetaxel—melanoma	5.93e-05	0.000605	CcSEcCtD
Ponatinib—Pruritus—Docetaxel—melanoma	5.85e-05	0.000597	CcSEcCtD
Ponatinib—Diarrhoea—Docetaxel—melanoma	5.66e-05	0.000577	CcSEcCtD
Ponatinib—Dizziness—Docetaxel—melanoma	5.47e-05	0.000558	CcSEcCtD
Ponatinib—ABCB1—lymph node—melanoma	5.27e-05	0.000999	CbGeAlD
Ponatinib—Vomiting—Docetaxel—melanoma	5.26e-05	0.000536	CcSEcCtD
Ponatinib—Rash—Docetaxel—melanoma	5.21e-05	0.000532	CcSEcCtD
Ponatinib—Dermatitis—Docetaxel—melanoma	5.21e-05	0.000531	CcSEcCtD
Ponatinib—Headache—Docetaxel—melanoma	5.18e-05	0.000528	CcSEcCtD
Ponatinib—Nausea—Docetaxel—melanoma	4.91e-05	0.000501	CcSEcCtD
Ponatinib—PDGFRA—Disease—HRAS—melanoma	8.33e-07	4.7e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—melanoma	8.31e-07	4.69e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—STAT3—melanoma	8.25e-07	4.65e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—NRAS—melanoma	8.23e-07	4.64e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FGF2—melanoma	8.21e-07	4.63e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK3—melanoma	8.21e-07	4.63e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—CDKN1A—melanoma	8.18e-07	4.62e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PTEN—melanoma	8.17e-07	4.61e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCND1—melanoma	8.16e-07	4.61e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK1—melanoma	8.12e-07	4.58e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—melanoma	8.12e-07	4.58e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—BRAF—melanoma	8.12e-07	4.58e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CG—melanoma	8.1e-07	4.57e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—melanoma	8.09e-07	4.56e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CTNNB1—melanoma	8.09e-07	4.56e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—melanoma	8.07e-07	4.55e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK3—melanoma	8.06e-07	4.55e-06	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—melanoma	8.05e-07	4.54e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—STAT3—melanoma	8.01e-07	4.52e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NRAS—melanoma	7.99e-07	4.51e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—melanoma	7.99e-07	4.51e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—STAT3—melanoma	7.99e-07	4.51e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ABCB1—melanoma	7.99e-07	4.51e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CA—melanoma	7.99e-07	4.51e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—melanoma	7.99e-07	4.51e-06	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—melanoma	7.98e-07	4.5e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NRAS—melanoma	7.97e-07	4.5e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—melanoma	7.97e-07	4.5e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—melanoma	7.96e-07	4.49e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—melanoma	7.96e-07	4.49e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—melanoma	7.94e-07	4.48e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—melanoma	7.93e-07	4.47e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—melanoma	7.92e-07	4.47e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—STAT3—melanoma	7.91e-07	4.46e-06	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—melanoma	7.91e-07	4.46e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF1—melanoma	7.91e-07	4.46e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1A—melanoma	7.9e-07	4.46e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—NRAS—melanoma	7.89e-07	4.45e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK3—melanoma	7.88e-07	4.45e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTEN—melanoma	7.88e-07	4.45e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—melanoma	7.84e-07	4.42e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NFKB1—melanoma	7.84e-07	4.42e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARG—melanoma	7.82e-07	4.41e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK1—melanoma	7.81e-07	4.41e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—melanoma	7.81e-07	4.41e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PRKCA—melanoma	7.8e-07	4.4e-06	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—melanoma	7.77e-07	4.38e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ERCC2—melanoma	7.74e-07	4.36e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MDM2—melanoma	7.68e-07	4.33e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK1—melanoma	7.67e-07	4.33e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—melanoma	7.67e-07	4.33e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—melanoma	7.67e-07	4.33e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—melanoma	7.67e-07	4.32e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK3—melanoma	7.65e-07	4.32e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAP2K1—melanoma	7.64e-07	4.31e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK3—melanoma	7.63e-07	4.31e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—melanoma	7.61e-07	4.3e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—melanoma	7.6e-07	4.29e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CD—melanoma	7.59e-07	4.28e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—melanoma	7.58e-07	4.28e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB2—melanoma	7.57e-07	4.27e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK3—melanoma	7.56e-07	4.26e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP17A1—melanoma	7.53e-07	4.25e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK1—melanoma	7.5e-07	4.23e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—melanoma	7.5e-07	4.23e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTEN—melanoma	7.48e-07	4.22e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CB—melanoma	7.47e-07	4.22e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—melanoma	7.44e-07	4.2e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—melanoma	7.42e-07	4.19e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—melanoma	7.38e-07	4.16e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—melanoma	7.37e-07	4.16e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	7.36e-07	4.15e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—melanoma	7.35e-07	4.15e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PRKCA—melanoma	7.35e-07	4.15e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—STAT3—melanoma	7.3e-07	4.12e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ERCC2—melanoma	7.29e-07	4.11e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—NRAS—melanoma	7.29e-07	4.11e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK1—melanoma	7.28e-07	4.11e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—melanoma	7.28e-07	4.11e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FGF2—melanoma	7.27e-07	4.1e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK1—melanoma	7.26e-07	4.1e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—melanoma	7.26e-07	4.1e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—melanoma	7.25e-07	4.09e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK1—melanoma	7.19e-07	4.06e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—melanoma	7.19e-07	4.06e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—melanoma	7.18e-07	4.05e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CD—melanoma	7.12e-07	4.02e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—melanoma	7.12e-07	4.02e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GNA11—melanoma	7.12e-07	4.01e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—melanoma	7.08e-07	4e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—melanoma	7.05e-07	3.98e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STAT3—melanoma	7.05e-07	3.98e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NRAS—melanoma	7.03e-07	3.97e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ALB—melanoma	7.03e-07	3.96e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—melanoma	7.02e-07	3.96e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—melanoma	7.01e-07	3.96e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1B—melanoma	7.01e-07	3.96e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CG—melanoma	7.01e-07	3.96e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—melanoma	6.99e-07	3.94e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK3—melanoma	6.98e-07	3.94e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—FASN—melanoma	6.96e-07	3.93e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—melanoma	6.88e-07	3.88e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—melanoma	6.88e-07	3.88e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—melanoma	6.86e-07	3.87e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—melanoma	6.86e-07	3.87e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC5A5—melanoma	6.85e-07	3.86e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MDM2—melanoma	6.8e-07	3.84e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—melanoma	6.79e-07	3.83e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—melanoma	6.79e-07	3.83e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—melanoma	6.78e-07	3.82e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARG—melanoma	6.77e-07	3.82e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK3—melanoma	6.73e-07	3.8e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB2—melanoma	6.71e-07	3.78e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—melanoma	6.69e-07	3.78e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—melanoma	6.66e-07	3.76e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK1—melanoma	6.64e-07	3.75e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—melanoma	6.64e-07	3.74e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CTNNB1—melanoma	6.63e-07	3.74e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CB—melanoma	6.62e-07	3.73e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GNAQ—melanoma	6.61e-07	3.73e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CD44—melanoma	6.61e-07	3.73e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—melanoma	6.56e-07	3.7e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—melanoma	6.55e-07	3.69e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—melanoma	6.52e-07	3.68e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—melanoma	6.52e-07	3.68e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—melanoma	6.51e-07	3.67e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—melanoma	6.5e-07	3.67e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1A—melanoma	6.47e-07	3.65e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTEN—melanoma	6.46e-07	3.64e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—melanoma	6.44e-07	3.63e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NFKB1—melanoma	6.43e-07	3.63e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK1—melanoma	6.41e-07	3.61e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—melanoma	6.41e-07	3.61e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—melanoma	6.36e-07	3.59e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP1B1—melanoma	6.34e-07	3.58e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—melanoma	6.32e-07	3.56e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—melanoma	6.3e-07	3.56e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—melanoma	6.27e-07	3.54e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—melanoma	6.27e-07	3.54e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—melanoma	6.24e-07	3.52e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—melanoma	6.24e-07	3.52e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1B—melanoma	6.21e-07	3.5e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CB—melanoma	6.2e-07	3.5e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CD—melanoma	6.17e-07	3.48e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—melanoma	6.16e-07	3.48e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—melanoma	6.15e-07	3.47e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—melanoma	6.11e-07	3.45e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CG—melanoma	6.11e-07	3.45e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—melanoma	6.1e-07	3.44e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ALB—melanoma	6.09e-07	3.43e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—melanoma	6.09e-07	3.43e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—melanoma	6.08e-07	3.43e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—melanoma	6.05e-07	3.41e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—melanoma	6.02e-07	3.4e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—melanoma	6e-07	3.39e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—melanoma	5.92e-07	3.34e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARG—melanoma	5.9e-07	3.33e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—melanoma	5.9e-07	3.33e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CTNNB1—melanoma	5.87e-07	3.31e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—melanoma	5.85e-07	3.3e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—melanoma	5.83e-07	3.29e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—melanoma	5.83e-07	3.29e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STAT3—melanoma	5.78e-07	3.26e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—melanoma	5.77e-07	3.26e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NRAS—melanoma	5.76e-07	3.25e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—melanoma	5.76e-07	3.25e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—melanoma	5.76e-07	3.25e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CG—melanoma	5.76e-07	3.25e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—melanoma	5.76e-07	3.25e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—melanoma	5.75e-07	3.24e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1A—melanoma	5.73e-07	3.23e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTEN—melanoma	5.72e-07	3.23e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NFKB1—melanoma	5.69e-07	3.21e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—melanoma	5.6e-07	3.16e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—melanoma	5.58e-07	3.15e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—melanoma	5.56e-07	3.14e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARG—melanoma	5.56e-07	3.14e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—melanoma	5.54e-07	3.12e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—melanoma	5.53e-07	3.12e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK3—melanoma	5.52e-07	3.11e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—melanoma	5.44e-07	3.07e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—melanoma	5.38e-07	3.03e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CB—melanoma	5.37e-07	3.03e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CD—melanoma	5.37e-07	3.03e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—melanoma	5.37e-07	3.03e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTEN—melanoma	5.36e-07	3.02e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—melanoma	5.33e-07	3.01e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—melanoma	5.33e-07	3e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—melanoma	5.32e-07	3e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ALB—melanoma	5.3e-07	2.99e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—melanoma	5.28e-07	2.98e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK1—melanoma	5.25e-07	2.96e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—melanoma	5.25e-07	2.96e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ABCB1—melanoma	5.22e-07	2.95e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—melanoma	5.16e-07	2.91e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—melanoma	5.16e-07	2.91e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—melanoma	5.15e-07	2.9e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—melanoma	5.14e-07	2.9e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT3—melanoma	5.11e-07	2.89e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NRAS—melanoma	5.1e-07	2.88e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—melanoma	5.1e-07	2.88e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—melanoma	5.1e-07	2.88e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CD—melanoma	5.06e-07	2.86e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ALB—melanoma	5e-07	2.82e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—melanoma	4.96e-07	2.8e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—melanoma	4.92e-07	2.78e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK3—melanoma	4.89e-07	2.76e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PRKCA—melanoma	4.81e-07	2.71e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ERCC2—melanoma	4.77e-07	2.69e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—melanoma	4.75e-07	2.68e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—melanoma	4.71e-07	2.65e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CB—melanoma	4.68e-07	2.64e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK1—melanoma	4.65e-07	2.62e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—melanoma	4.65e-07	2.62e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTEN—melanoma	4.64e-07	2.62e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—melanoma	4.64e-07	2.62e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—melanoma	4.56e-07	2.57e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—melanoma	4.54e-07	2.56e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CB—melanoma	4.41e-07	2.49e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—melanoma	4.41e-07	2.49e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—melanoma	4.39e-07	2.48e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—melanoma	4.37e-07	2.47e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—melanoma	4.31e-07	2.43e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—melanoma	4.22e-07	2.38e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTEN—melanoma	4.05e-07	2.28e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—melanoma	4.04e-07	2.28e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—melanoma	4.03e-07	2.28e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—melanoma	3.9e-07	2.2e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTEN—melanoma	3.81e-07	2.15e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—melanoma	3.78e-07	2.13e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CG—melanoma	3.76e-07	2.12e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—melanoma	3.73e-07	2.11e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—melanoma	3.72e-07	2.1e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARG—melanoma	3.63e-07	2.05e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—melanoma	3.57e-07	2.02e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CD—melanoma	3.31e-07	1.87e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—melanoma	3.3e-07	1.86e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—melanoma	3.28e-07	1.85e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALB—melanoma	3.27e-07	1.84e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—melanoma	3.09e-07	1.74e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CB—melanoma	2.88e-07	1.63e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—melanoma	2.86e-07	1.61e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—melanoma	2.85e-07	1.61e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—melanoma	2.69e-07	1.52e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—melanoma	2.68e-07	1.51e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTEN—melanoma	2.49e-07	1.41e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—melanoma	2.33e-07	1.32e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—melanoma	2.2e-07	1.24e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—melanoma	1.76e-07	9.92e-07	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—melanoma	1.44e-07	8.1e-07	CbGpPWpGaD
